Skip to main content

28.02.2024 | original report

Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma

verfasst von: Changbin Wang, Ran Zhang, Xiaorong Sun, Ligang Xing

Erschienen in: memo - Magazine of European Medical Oncology

Einloggen, um Zugang zu erhalten

Summary

Background

The purpose of this study was to assess the correlation between textural features from 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) or computed tomography (CT) and EGFR mutation status in patients with stage IV adenocarcinoma lung cancer.

Methods

In all, 71 patients who were diagnosed with stage IV adenocarcinoma lung cancer between April 2014 and August 2018 were included in this study. 18F-FDG-PET/CT scanning and EGFR mutation tests were performed before targeted molecular therapy. Textural features were extracted from manually segmented volumes of tumors, and highly dependent features were excluded. Multivariate logistic regression analysis was used to establish predictive models for detection of EGFR mutations. Receiver operating characteristic (ROC) curves were applied to evaluate areas under the curves (AUCs) of each model.

Results

Of the 71 patients, 39 (54.9%) were EGFR mutation and 32 (45.1%) showed wild-type. EGFR mutation status was significantly associated with female sex (P = 0.026). In multivariate analysis, three PET (co-occurrence contrast, intensity-size-zone low-intensity large-zone emphasis, and texture spectrum max spectrum) and two CT quantitative features (intensity-size-zone high-intensity zone emphasis and normalized co-occurrence second angular moment) were independent predictors of EGFR mutation status. The predictive model generated from combined clinical and textural features showed a better predictive value than the model from textural features alone (AUC 0.897 vs 0.864).

Conclusions

Textural features combined with clinical features could establish a model for improving the predicting power of EGFR mutation status in patients with stage IV adenocarcinoma lung cancer.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5–29. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5–29.
2.
Zurück zum Zitat von Verschuer U, Schnell R, Tessen HW, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer—final results from the prospective German TLK cohort study. Lung Cancer. 2017;112:216–24.CrossRef von Verschuer U, Schnell R, Tessen HW, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer—final results from the prospective German TLK cohort study. Lung Cancer. 2017;112:216–24.CrossRef
3.
Zurück zum Zitat Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.CrossRefPubMed Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.CrossRefPubMed
4.
Zurück zum Zitat Mok TS, Wu Y‑L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed Mok TS, Wu Y‑L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
5.
Zurück zum Zitat Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Clin Pharm Ther. 2013;105(9):595–605. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis. J Clin Pharm Ther. 2013;105(9):595–605.
6.
Zurück zum Zitat Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3):839.CrossRefPubMed Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(3):839.CrossRefPubMed
7.
Zurück zum Zitat Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497.ADSCrossRefPubMed Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497.ADSCrossRefPubMed
8.
Zurück zum Zitat Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer. Cancer Res. 2004;64(24):8919.CrossRefPubMed Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer. Cancer Res. 2004;64(24):8919.CrossRefPubMed
9.
Zurück zum Zitat Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
10.
Zurück zum Zitat Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39(2):366.CrossRefPubMed Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012;39(2):366.CrossRefPubMed
11.
Zurück zum Zitat Rios Velazquez E, Parmar C, Liu Y, et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res. 2017;77(14):3922–30.CrossRefPubMed Rios Velazquez E, Parmar C, Liu Y, et al. Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res. 2017;77(14):3922–30.CrossRefPubMed
12.
13.
Zurück zum Zitat Yang B, Wang QG, Lu M, et al. Correlations study between (18)F-FDG PET/CT metabolic parameters predicting epidermal growth factor receptor mutation status and prognosis in lung adenocarcinoma. Front Oncol. 2019;9:589.CrossRefPubMedPubMedCentral Yang B, Wang QG, Lu M, et al. Correlations study between (18)F-FDG PET/CT metabolic parameters predicting epidermal growth factor receptor mutation status and prognosis in lung adenocarcinoma. Front Oncol. 2019;9:589.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280(1):271–80.CrossRefPubMed Liu Y, Kim J, Qu F, et al. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma. Radiology. 2016;280(1):271–80.CrossRefPubMed
15.
Zurück zum Zitat Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 2006;1(5):413–6.CrossRefPubMed Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 2006;1(5):413–6.CrossRefPubMed
16.
Zurück zum Zitat Zhou JY, Zheng J, Yu ZF, et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 2015;25(5):1257–66.CrossRefPubMed Zhou JY, Zheng J, Yu ZF, et al. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Eur Radiol. 2015;25(5):1257–66.CrossRefPubMed
17.
Zurück zum Zitat Kim H, Park C, Keam B, Park S, Kim M, Kim T, et al. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. PLoS ONE. 2017;12:e187500.CrossRefPubMedPubMedCentral Kim H, Park C, Keam B, Park S, Kim M, Kim T, et al. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors. PLoS ONE. 2017;12:e187500.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Park S, Ha S, Lee S, Paeng J, Keam B, Kim T, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13:e189766.CrossRefPubMedPubMedCentral Park S, Ha S, Lee S, Paeng J, Keam B, Kim T, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13:e189766.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.ADSCrossRefPubMed Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.ADSCrossRefPubMed
20.
Zurück zum Zitat Zhou B, Xu J, Tian Y, Yuan S, Li X. Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lung cancer: A preliminary study. Thora Cancer. 2018;9(10):1235–40.CrossRef Zhou B, Xu J, Tian Y, Yuan S, Li X. Correlation between radiomic features based on contrast-enhanced computed tomography images and Ki-67 proliferation index in lung cancer: A preliminary study. Thora Cancer. 2018;9(10):1235–40.CrossRef
21.
Zurück zum Zitat Ozkan E, West A, Dedelow JA, et al. CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung. Am J Roentgenol. 2015;205(5):1016–25.CrossRef Ozkan E, West A, Dedelow JA, et al. CT gray-level texture analysis as a quantitative imaging biomarker of epidermal growth factor receptor mutation status in adenocarcinoma of the lung. Am J Roentgenol. 2015;205(5):1016–25.CrossRef
22.
Zurück zum Zitat Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441–448 e446. Liu Y, Kim J, Balagurunathan Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer. 2016;17(5):441–448 e446.
23.
Zurück zum Zitat Wang S, Shi J, Ye Z, et al. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J. 2019;53(3). Wang S, Shi J, Ye Z, et al. Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning. Eur Respir J. 2019;53(3).
24.
Zurück zum Zitat Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier P‑P, Souquet P‑J. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: Exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 2013;191(5):491–9.CrossRefPubMed Locatelli-Sanchez M, Couraud S, Arpin D, Riou R, Bringuier P‑P, Souquet P‑J. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: Exons 18–21 sequencing results of 753 patients and subsequent clinical outcomes. Lung. 2013;191(5):491–9.CrossRefPubMed
25.
Zurück zum Zitat Cheng N‑M, Fang DY‑H, Tung-Chieh CJ, et al. Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T‑Stage Oropharyngeal Squamous Cell Carcinoma. J Nucl Med. 2013;54:1703–9.CrossRefPubMed Cheng N‑M, Fang DY‑H, Tung-Chieh CJ, et al. Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T‑Stage Oropharyngeal Squamous Cell Carcinoma. J Nucl Med. 2013;54:1703–9.CrossRefPubMed
26.
Zurück zum Zitat Stephen Y, Keisha M, Michalis A, et al. Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer. Plos One. 2014;9(12:e115510. Stephen Y, Keisha M, Michalis A, et al. Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer. Plos One. 2014;9(12:e115510.
27.
Zurück zum Zitat Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.CrossRefPubMed Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJR. Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40(1):133–40.CrossRefPubMed
28.
Zurück zum Zitat W‑s L, L‑j Z. Pang Q‑s, Yuan Z‑y, Li B, Wang P. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol. 2013;31(1:771. W‑s L, L‑j Z. Pang Q‑s, Yuan Z‑y, Li B, Wang P. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol. 2013;31(1:771.
29.
Zurück zum Zitat Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24(1):48–54.CrossRefPubMedPubMedCentral Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24(1):48–54.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6(1):49–69.CrossRef da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6(1):49–69.CrossRef
31.
Zurück zum Zitat Park S, Ha S, Lee S‑H, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13(1):e189766–e189766.CrossRefPubMedPubMedCentral Park S, Ha S, Lee S‑H, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE. 2018;13(1):e189766–e189766.CrossRefPubMedPubMedCentral
Metadaten
Titel
Prediction of epidermal growth factor receptor mutation status by textural features in stage IV lung adenocarcinoma
verfasst von
Changbin Wang
Ran Zhang
Xiaorong Sun
Ligang Xing
Publikationsdatum
28.02.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00961-1

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.